我院2007-2009年门诊口服抗肿瘤西药应用分析  

Analysis of the Utilization of Oral Antineoplastic Western Medicine in Outpatient Department of Our Hospital during the Period of 2007-2009

作　　者：顾玉红[1] 蓝玉进[1] 杜佳新[2] 

机构地区：[1]哈尔滨医科大学附属第三医院,哈尔滨市150081 [2]哈尔滨医科大学附属第一医院,哈尔滨市150001

出　　处：《中国药房》2011年第18期1661-1663,共3页China Pharmacy

摘　　要：目的:了解我院门诊口服抗肿瘤西药的应用情况。方法:对我院2007-2009年门诊口服抗肿瘤西药的销售金额、用药频度(DDDs)、日均费用(DDC)等进行统计、分析。结果:我院门诊口服抗肿瘤西药的销售金额和DDDs呈逐年上升趋势,2008年口服抗肿瘤西药的总销售金额比2007年增长2.28%,2009年比2007年增长了4.01%。吉非替尼片的销售金额连续3年稳居首位;DDC最少的是枸椽酸托瑞米芬片。结论:我院门诊口服抗肿瘤西药的应用基本合理。OBJECTIVE：To investigate the utilization of oral antineoplastic western medicines in outpatient department of our hospital.METHODS：The utilization of oral antineoplastic western medicines in outpatient department of our hospital during 2007-2009 were analyzed statistically in respect of consumption sum,DDDs,DDC,etc.RESULTS：The consumption sum and DDDs of oral antineoplastic western medicines in our hospital for outpatients during 2007-2009 took an obvious rising trend.The total consumption sum of oral antineoplastic western medicines in 2008 increased by 2.28% than 2007,and by 4.01% in 2009 than 2007.Gefitinib tablets occupied the first place in the list of consumption sum for 3 years.The DDC of Toremifene citrate tablets was the minimum one.CONCLUSION：The utilization of oral antineoplastic western medicines in outpatient department of our hospital is rational on the whole.

关 键 词：口服抗肿瘤西药 用药频度 日均费用 

分 类 号：R969.3[医药卫生—药理学] R287[医药卫生—药学]